Evaluation of the Integrated E-Z Split Key Cup II for Rapid Detection of Twelve Drug Classes in Urine

Size: px
Start display at page:

Download "Evaluation of the Integrated E-Z Split Key Cup II for Rapid Detection of Twelve Drug Classes in Urine"

Transcription

1 Technical Note Evaluation of the Integrated E-Z Split Key Cup II for Rapid Detection of Twelve Drug Classes in Urine Dina N. Greene, Christopher M. Lehman, and Gwendolyn A. McMillin* University of Utah Health Sciences Center, Department of Pathology, Salt Lake City, Utah Abstract The availability of point-of-care (POC) medical devices for drug testing has surged. Reduction in turnaround time, and hence, rapid results are attractive, particularly to acute care facilities, rehabilitation facilities and specialized clinics such as pain management clinics. Here we describe our validation results for the Integrated E-Z Split Key Cup II, a low-cost, rapid urine test that utilizes competitive immunoassay technology to detect 12 drugs or drug classes of commonly abused drugs. Positivity is based on the absence of a colored band at a labeled portion of the detection strip; a negative result produces a distinct, colored band. Using reagent-grade standards, the apparent cut-off for each of the drugs was challenged. The stability of the results was monitored over time. Five urine samples known to be negative for all drug categories and 24 patient samples confirmed positive for a total of 95 drugs and/or drug metabolites claimed to be detected by the device were tested. Adulterants and potential cross-reacting compounds were also evaluated. One false-positive result for benzodizepines was observed. One false-negative result for barbiturates was observed, but was resolved. Overall, the cups demonstrated excellent sensitivity, specificity, and diagnostic efficiency for all drugs represented. Introduction Point-of-care (POC) testing provides a means for health practitioners to receive accurate and timely laboratory test results at the bedside. By definition, a POC test is performed near the patient, outside of a clinical laboratory, and therefore has the potential to make results available within minutes of specimen collection. Many POC testing methods are subject to minimal regulatory requirements, and can be performed with specimens such as urine, capillary blood, or oral fluid, that do not require phlebotomy. POC testing may improve patient counseling * Author to whom correspondence should be addressed: Department of Pathology, University of Utah School of Medicine, ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT gwen.mcmillin@aruplab.com. and management because results are available during a patient visit. Successful examples of POC testing used routinely include glucose and prothrombin time monitoring to guide glycemic and anti-coagulation management. Advances in technology have increased the availability of POC devices, and the potential clinical benefits are attractive; however, to be effective, POC must be easy to use, cost effective, and meet accepted quality standards. Recent work has shown that many POC devices fail to meet quality standards, emphasizing the need for stringent validation criteria (1). Inappropriate drug use and drug abuse remains a common problem clinically. It is well recognized that self-reporting of drug use is of limited accuracy and utility. For example, when screening for prenatal exposure to methamphetamine, a notable percent of women that denied abuse gave birth to infants who tested positive (2). Further, a large review of national surveys showed that although some people will self-report drug history accurately, external factors such as pregnancy and need for approval increase the rate of inaccurate reporting (3). Because patient management decisions regarding drug use and abuse depend on accurate drug histories, detection of drugs using POC testing may benefit outpatient drug rehabilitation facilities, whether used to monitor abstinence, verify compliance with prescribed therapy, or identify inappropriate drug use. Specifically, a counselor may better manage the patient session having real-time drug screen results available rather than waiting for results from a test that was sent to a central laboratory and may require several days to generate results. Here, we evaluate the performance of the Integrated E-Z Split Key Cup II, a user-friendly and cost-effective POC device that detects 12 commonly abused drugs (amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine, marijuana, methadone, methamphetamine, MDMA, opiates, oxycodone, and propoxyphene). Using a validation procedure consistent with CLIA guidelines, we evaluated the ability of the drug screen cup to detect purified reagent standards for each drug class at concentrations above and below the cutoff; the stability of the results over time; the ability of the cup to accurately identify multiple drugs in patient urine; and the effect of potential cross-reacting, interfering compounds, and common adulter- 46 Reproduction (photocopying) of editorial content of this journal is prohibited without publisher s permission.

2 ants on the results. To the best of our knowledge, this is the only published validation for a POC device that detects 12 drug classes. Materials and Methods Table I. Limit of Detection Measured for Each Drug Class Published Confirmed Drug Reference Cutoff Concentration LOD Class Standard (ng/ml) (ng/ml) Amphetamine d,l-amphetamine Amphetamine d-amphetamine * Barbiturates Secobarbital Benzodiazepines Oxazepam Buprenorphine Buprenorphine Cocaine Benzoylecognine Marijuana 11-nor- 9 -THC-9-COOH Methadone Methadone Methamphetamine d,l-methamphetamine Methamphetamine d-methamphetamine * MDMA MDMA Opiate Morphine Oxycodone Oxycodone Propoxyphene Propoxyphene * These values were calculated using measured cut offs for the racemic mixture and the published cut offs for d,l and d isoforms (amphetamines) or d and l isoforms (methamphetamine). 3,4-Methylenedioxymethamphetamine. POC device The Integrated E-Z Split Key Cup II (Lot DOA ) was purchased from Rapid Detect (Poteau, OK). The manufacturer s published cutoffs for the 12 drug classes detected by the device are listed in Table I. The drugs are detected based on competitive immunoassays. There are six test strips/cup; each strip detects specific drugs. Each strip also has its own colored control band. Urine is distributed into the cup. The key is removed from the cap and pushed into the siding of the apparatus. This unlocks the urine and allows it to wick the membrane, traveling to the top of the membrane via capillary action. Embedded in the membrane are drug-protein conjugates; each test strip has corresponding anti-drug mouse monoclonal antibodies that will travel with the urine. The anti-drug antibodies are labeled with a colored conjugate. Therefore, if there is drug in the urine, the drug will sequester the antibody, and no band will appear at the specific area of the membrane containing the drug-protein conjugate. In contrast, if the patient is negative for a drug, the anti-drug antibody will migrate to and bind the embedded drug, which is visualized by a colored band. More specifically, if urine is positive for a drug, the band is absent; if urine is negative for a drug, the band is present (Figure 1). The control band on each strip is used to detect proper volume of specimen, membrane wicking, and correct procedural technique. The control band does not specifically detect the presence of urine. Embedded in the membrane at the control position is rabbit IgG. Disbursed with the anti-drug mouse monoclonal antibodies are color conjugated goat polyclonal anti-rabbit IgG. Hence, any liquid that properly moistens the membrane will result in the appearance of a strong band in the control region of the strip. Limit of detection and time course study The cutoff for each drug was challenged using Cerilliant purified reference standards (Round Rock, TX). The standard specific to the drug class was the calibrator published in the product package insert. The standards were run using 0%, 25%, 50%, 75%, 100%, 125%, and, if needed, 150% of the apparent drug-specific cutoff. We used five separate cups for each percent tested and defined our limit of detection to be the concentration that gave a positive drug result in all five cups after 5 min, consistent with manufacturer s instructions. To evaluate the stability of test results, the cups were re-read after 30, 60, 120, and 1440 min. Figure 1. Images generated by photocopying the Integrated E-Z Split Key Cup II after screening urine positive for methamphetamine, amphetamine, and propoxyphene. Positive control is indicated by the C ; drug tested indicated either by number or T. Patient urine samples Patient urine previously confirmed positive or negative by validated gas chromatography mass spectrometry (GC MS) or liquid chromatography (LC) tandem MS assays for drugs of abuse were pooled to create 24 samples containing various amounts of the drugs of interest (2 5 drugs/urine pool, see Table II for a detailed description of sample composition) and 5 negative samples. If necessary, the pools were diluted with blank urine. The 24 drug-positive pools and 5 drug-negative urines were blinded before analysis. Thirty-five milliliters of the 47

3 Table II. Detailed Description of the 24 Patient Samples Screened Using the EZ Cup Drug(s) Concentration Positive Using Sample Present (ng/ml) E-Z Cup 1 THC 160 THC Morphine 420 Opioids Oxycodone 170 Oxycodone Amphetamine 170 Amphetamine Methamphetamine 4700 Methamphetamine Methadone 460 Methadone 2 THC 95 THC Benzoylecognine 1220 Cocaine Methamphetamine 2000 Methamphetamine Amphetamine 360 Amphetamine 3 THC 65 THC Lorazepam 150 Benzodiazepines Alprozolam 30 α-hydroxyalprazolam Aminoclonazepam 150 Amphetamine 3680 Amphetamine Methamphetamine 2600 Methamphetamine 4 THC 210 THC Nordiazepam 830 Benzodiazepines Oxazepam 1660 Temazepam 1920 Lorazepam 470 Morphine 350 Opioids Oxycodone 550 Oxycodone Norbuprenorphine 13 Buprenorphine 5 THC 60 THC MDMA 410 MDMA Oxycodone 135 Oxycodone Benzoylecognine 280 Cocaine 6 THC 55 THC MDMA 600 MDMA Nordiazepam 450 Benzodiazepines Oxazepam 640 Temazapam 340 Alprazolam 50 Methadone 1600 Methadone Propoxyphene 370 Propoxyphene 7 α-hydroxyalprazolam 180 Benzodiazepines 7-Aminoclonazepam 40 Alprazolam 50 Nordiazepam 280 Oxazepam 1100 Temazepam 880 Amphetamine 4690 Amphetamine Oxycodone 2800 Oxycodone Morphine 3000 Opioids Propoxyphene 310 Propoxyphene 8 Alprazolam 370 Benzodiazepines Amphetamine 2000 Amphetamine urine in question was allowed to react in the drug screen cup for 5 min before results were read. If there was a false-positive or false-negative result, the urine was poured into a fresh cup to assess reproducibility. If a specimen was positive for a drug that was unexpected, the drug identity was confirmed and the concentration was quantified using an appropriate, previously validated GC MS or LC MS MS assay. The Institutional Review Board of the University of Utah in Salt Lake City, Utah approved all studies using human samples. Adulterants and additional drug specificity The following adulterants were individually dissolved in 30 ml drug positive urine: 5 ml dry eye drops, 5 g Comet Cleaner with Bleach, 3 ml Backdown antibacterial hand soap, 5 ml 5.0% gluteraldehyde, 5 ml 1.0 M sodium nitrite, 6.5 g pyridinium chlorochromate (PCC), and 5 ml 0.1 M acetic acid. The urine used had previously screened positive for multiple drugs, including THC. Further adulteration studies were accomplished by testing 30 ml of non-urine liquid: Monster energy drink, Kroger sterile eye drops, and water. For all screens, results were read after incubating for 5 min. Cross-reactivity was assessed using either purified reference standards (Cerilliant) or patient samples confirmed positive for the drug. The standards or the patient samples were diluted in blank urine, and results were read after 5 min. Results Limit of detection and time course The limit of detection was defined as the drug concentration that gave a positive result for all 5 cups after 5 min. This value was identical to the manufacturer s published cutoff concentration for the following drug classes: buprenorphine, cocaine, opiates, and propoxyphene (Table I). Three of the drug classes showed a limit of detection at 125% of the cutoff concentration: opiates, barbiturates, and marijuana. Two drug classes, methadone and benzodiazepines, required 150%; 3,4-methylenedioxymethamphetamine (MDMA) was the only 48

4 Table II (continued). Detailed Description of the 24 Patient Samples Screened Using the EZ Cup Drug(s) Concentration Positive Using Sample Present (ng.ml) E-Z Cup 8 Buprenorphine 920 Buprenorphine Methamphetamine 1230 Methamphetamine 9 Oxycodone 750 Oxycodone Benzoylecognine 640 Cocaine Norbuprenorphine 25 Buprenorphine 10 Methadone 1110 Methadone Morphine 840 Opioids Buprenorphine 150 Buprenorphine Benzodiazepines* 11 Hydromorphone 40 Opioids Morphine 1510 Oxycodone 400 Oxycodone Oxymorphone Lorazepam 350 Benzodiazepines Butalbitol 4830 Barbiturates Codeine 340 Opioids Morphine 11 Methadone 780 Methadone Oxycodone 1860 Oxycodone Propoxyphene 210 Propoxyphene Benzoylecognine 60 Cocaine Norbuprenorphine 7 Buprenorphine Buprenorphine-glucuronide MDMA 2000 MDMA Methamphetamine Propoxyphene 26 Propoxyphene Butalbitol* Oxazepam 2930 Benzodiazepines Lorazepam 380 Methamphetamine 800 Methamphetamine Amphetamine 1550 Amphetamine MDMA 400 MDMA Propxyphene 1370 Propoxyphene 15 Methadone 475 Methadone Morphine 830 Opioids Codeine 90 6-Acetylmorphine 170 Methamphetamine 2030 Methamphetamine MDMA 480 MDMA THC 4 THC 16 Propoxyphene 90 Propoxyphene Amphetamine 3200 Amphetamine Codeine 510 Opioids Buprenorphine 9 Buprenorphine Norbuprenorphine 29 Norbuprenorphine-glucuronide 1100 THC 18 THC * False-positive or false-negative result. drug to give consistent positive results at 75% of the expected value. The observed cutoff levels for methamphetamine and amphetamine were measured using a racemic mixture standard. The antibodies against these stimulants are designed to more specifically detect the illegal d-form of the drugs, and hence the published cutoff for the racemic mixture is greater. The observed cutoffs for the racemic mixtures were much lower (< 45%) than the published cutoffs: 1250 ng/ml for both amphetamine and methamphetamine compared to the published 3000 and 4500 ng/ml, respectively. Using these values and assuming that there would be a proportional increase in sensitivity with a pure d-isomer, the cutoff concentrations for d-amphetamine and d-methamphetamine were calculated. For example, the measured LOD was 58% less than the published LOD for the racemic mixture of amphetamines. Thus, we assumed that the d-isomer LOD would behave similarly, and the LOD was calculated to be 58% less than the manufacturer states. A comparison of the published cutoff concentrations and the validated concentrations are listed in Table I. One advantage of most POC devices, including the Integrated E-Z Split Key Cup II, is the rapid production of results. According to the manufacurer s instructions, results should be visualized after 5 min. In order to determine how incubation time influences test results, cups used for the LOD study were resulted after 5, 30, 60, 120, and 1440 min. The results were similar for every concentration tested. The results for the cups incubated with 125% or similar concentration of the published cutoff are shown in Table III. In general, results were stable up to 60 min, but began to give false-negative results after 2 h. Results interpreted after 1440 min were markedly affected, producing a significant amount of false-negative results. Of note, the two drugs that were determined to require 150% of standard to produce consistently positive results at 5 min (methadone and benzodiazepines) had improved sensitivity after 30 min. These two drugs also showed consistently positive results after 120 min using concentrations at 100% of 49

5 the published cutoffs; concentrations at 75% of the published cutoff did not give positive results, even after overnight incubation. Patient urine samples Twenty-four urine samples confirmed positive for a total of 95 drugs of abuse and 5 urine samples negative for all relevant drugs were screened (29 samples total; Tables II, IV, and V). One false-positive and one-false negative result were observed. The false-positive result was for benzodiazepines. Given that 13 true-positive urines screened positive and 26 true-negative Table II (continued). Detailed Description of the 24 Patient Samples Screened Using the EZ Cup Drug(s) Concentration Positive Using Sample Present (ng/ml) E-Z Cup Benzoylecognine 170 Cocaine Phenobarbitol 2370 Barbiturates Temazepam 270 Benzodiazepines Oxazepam 325 Nordiazepam Methamphetamine 6100 Methamphetamine THC 6 THC Phenobarbitol 1030 Barbiturates Amphetamine 1600 Amphetamine Lorazepam 60 Benzodiazepines 7-Aminoclonazepam 30 Buprenorphine-glucuronide 5 Buprenorphine Norbuprenorphine 4 Norbuprenorphine-glucuronide THC 2 THC Phenobarbitol 590 Barbiturates α-hydroxyalprazolam 900 Benzodiazepines Alprazolam 320 Benzoylecognine 700 Cocaine 20 Methamphetamine 5300 Methamphetamine Amphetamine 830 Amphetamine Propoxyphene 440 Propoxyphene 21 Tramadol Hydrocodone 8300 Opioids Oxazepam 130 Benzodiazepines 23 7-Aminoclonazepam 750 Benzodiazepines Hydrocodone 1050 Opioids THC 16 THC 24 Fentanyl 5000 THC 25 THC Nordiazepam 440 Benzodiazepines Oxazepam 1800 Temazapam Aminoclonazepam 580 Phenobarbitol 404 Barbiturates Oxycodone 400 Oxycodone samples screened negative, the specificity and sensitivity were calculated to be 96.3% and 100.0%, respectively. The diagnostic efficiency was 96.6%. The root cause of the false-positive urine result was evaluated by testing for the presence of a reacting compound (22 benzodiazepines/metabolites were examined); however, none was detected. The sample also tested negative for sertraline, a commonly prescribed antidepressant that the manufacturer suggests can cause positive benzodiazepine results, leaving the false positive unresolved. The false-negative result was for barbiturates. This sample was confirmed to be positive for butalbitol at concentrations well above the cutoff. When the specimen was decanted into a new screening cup, the barbiturates gave a positive result, suggesting that there may be variation between cups. Thus, with 5 true-positive screening results and 23 true-negative screening results, the sensitivity, specificity, and diagnostic efficiency are 83.3%, 100.0%, and 96.6%, respectively. All other drug classes had a specificity, sensitivity, and diagnostic efficiency of 100% for the samples tested. It is noteworthy that many of the drugs gave positive results at concentrations well below the published cutoff and the limit of detection quantified using purified standards. This result is not unexpected, considering the large amounts of metabolites structurally similar to the parent drug of interest that are expected to be present in the urine of drug users. In accordance, the patient results for methadone were positive at levels well below the reagent standard cutoff because the assay recognizes both methadone and 2-ethylidene- 1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) equally. Similarly, high levels of MDMA (> 2000 ng/ml) can lead to falsepositive results for methamphetamine. Although MDMA is not a metabolite of methamphetamine, the structure of MDMA and the structures of MDMA metabolites are very similar to methamphetamine. This cross-reactivity was reported by the manufacturer and supported by our results (Table IV). Adulterants The use of household or proprietary chemicals to alter drug screen results is recognized to occur. Thus, knowing the effect that frequently used adulterants might have on the Integrated E-Z Split Key Cup II is important. Samples that had previously screened positive for multiple drug classes were manipulated with liquid soap, Kroger sterile eye drops, pow-

6 dered bleach, acetic acid, gluteraldehyde, or sodium nitrite. There were no instances of these substances giving a falsenegative result; gluteraldehyde gave a false-positive result for methamphetamine. Both the liquid soap and the gluteraldehyde weakened the intensity of the control band. False positives Table III. Time Course of Results Using Purified Reagent Standards at 125% the Published Cutoff* Drug (min) (min) (min) (min) (min) d,l-methamphetamine d,l-mdma nor- 9 -THC-9 COOH Oxazepam (BZO) Methadone Secobarbitol (BAR) d,l-amphetamine Morphine Oxycodone Propoxyphene Benzoylecgonine (COC) Buprenorphine * The results represent the number of cups positive from a total of 5. Bold results indicate that 100% of cups were positive for a drug. or weakened intensity of negative bands is expected after the addition of these substances, as all are known to interfere with protein interactions, and hence, antibody antigen interactions. Most interesting was the sample adulterated with PCC. The addition of PCC inhibited the binding of all antibodies to the membrane giving a false-positive result for all drugs being tested, while also blocking the formation of the control band. A more troubling result was obtained after the addition of non-urine liquid to the screening cup. Because the control band is only used to detect proper volume of specimen, membrane wicking, and correct procedural technique, it will produce a colored line regardless of the matrix added to the cup, not specifically in the presence of urine. The addition of water, Monster energy drink, or Kroger sterile eye drops all gave results that mimicked blank urine. Cross-reactivity of additional drugs The manufacturer provided an extensive list of compounds that do or do not cross-react with the various drug classes screened by the Integrated E-Z Split Key Cup II. However, there were still commonly prescribed or abused drugs that were not present on their list. For these compounds, patient urine or blank urine plus purified reference standard were screened using the cup at concentrations similar to what would be observed in urine. Patient urine was used to test cross-reactivity of fentanyl (5000 ng/ml) and tramadol (16,030 ng/ml); purified reagent standards were used to test cross-reactivity of Table IV. Overview of Patient Urine Screening Results: Compounds that Screened Positive for the Various Drug Classes, the Range of Concentrations Present in the Specimens, the Number of Samples (n) for the Specific Compound, and the Mean Concentration of All Positive Specimens Concentration % Drug Range Mean Cross- Class Compound n (ng/ml) (ng/ml) Reactivity* Amphetamines Amphetamine % Cocaine Benzoylecognine % Methamphetamine Methamphetamine % MDMA % MDMA MDMA % Barbiturates Butalbitol % Phenobarbitol % Methadone Methadone % Opiates Morphine % Codeine % Hydrocodone % Oxycodone Oxycodone % Propoxyphene Propoxyphene % Buprenorphine Buprenorphine % Norbuprenorphine % Marijuana 11-nor- 9 -THC-9 COOH % * Estimated from the detection concentration listed in the package insert by dividing the LOD for the drug class standard by the LOD of the specific drug present. 51

7 tapentadol (2500 ng/ml), phentermine (17,000 ng/ml), ritalinic acid (17,000 ng/ml), selegiline (10 ng/ml), desmethylselegiline (1000 ng/ml), zolpiclone (5000 ng/ml), and zolpidem (5000 ng/ml). The results revealed no apparent cross-reactivity with any of the tested compounds. markedly decreased compared to surrounding bands, the specimen was resulted as positive. On confirmation, the specimen was found to contain quantities of benzodiazepines well below the cutoff. Thus, interpretation of results may be subjective. To Discussion Rapid detection of drugs in patient specimens may be beneficial to acute care facilities, rehabilitation facilities, and specialty clinics such as those used for pain management, and emergency departments. In this study we evaluated the performance of the Integrated E-Z Split Key Cup II, a chromatographic immunoassay that qualitatively detects multiple drugs and drug metabolites in urine. Overall, the device met quality standards, displaying high diagnostic sensitivity, specificity, and diagnostic efficiency. The device is accurate, easy to use, and cost effective, making it an ideal screen for institutions where timely results can have a profound effect on patient care. The tight seal of the cup allows the results to easily be photocopied (Figure 1), facilitating patient record maintenance and standardization of reporting procedures. Although CLIA has identified the cup to be a moderately complex test, the drug screening cup is remarkably easy to use. Many POC devices are waived, meaning that the basic regulatory guideline is to follow the manufacturer s instructions. However, because the Integrated E-Z Split Key Cup II is a moderately complex test, the institution employing the screen must follow more stringent guidelines regarding the training of testing personnel (including regular competency evaluations). Most importantly, when implementing a moderately complex test, the institution must demonstrate proficiency through participation in an accredited program such as that offered through the College of American Pathologists. The results of the cup are generally very clear, especially if the urine is negative for a drug/multiple drugs. However, if the cup is closely scrutinized the reader may be able to convince himself or herself that a drug is or is not present. For example, the cup used to analyze benzodiazepine sample 9 (Table V) showed a very faint band. Because the intensity was Table V. Concentrations of Benzodiazepines and Metabolites Present in Patient Urine Samples that Tested Positive for Benzodiazepines Using the E-Z Cup Concentration % Cross-Reactivity Sample Benzodiazepine (ng/ml) Relative to Standard* 1 Lorazepam % Alprazolam % α-hydroxyalprazolam % 7-Aminoclonazepam % 2 Nordiazepam % Oxazepam % Temazepam % Lorazepam % 3 Nordiazepam % Oxazepam % Temazepam % Alprazolam % 4 α-hydroxyalprazolam % 7-Aminoclonazepam 40 40% Alprazolam % Nordiazepam % Oxazepam % Temazepam % 5 Alprazolam % 6 Lorazepam % 7 Oxazepam % Lorazepam % 8 Temazepam % Oxazepam % 9 Lorazepam 60 20% Nordiazepam 70 80% 7-Aminoclonazepam 30 40% 10 α-hydroxyalprazolam % Alprazolam % 11 7-Aminoclonazepam % 12 Nordiazepam % Oxazepam % Temazepam % 7-Aminoclonazepam % 13 Oxazepam % * Estimated from the detection concentration listed in the package insert by dividing the LOD for the drug class standard by the LOD of the specific drug present. 52

8 minimize bias of results, it is helpful to employ the following guidelines: 1. read the results at least an arm s length distance; 2. blind the reader to the patient name; and 3. run a negative control or blank specimen in parallel with the patient sample. Archiving a photocopy of the cup may assist with resolving any discrepancies or inconsistencies over time and among analysts. Confirmation of any result inconsistent with expectations will also improve interpretation of results. However, sensitivity for detection of drugs, and hence, interpretation of results, is also a function of available confirmation testing. Thus, positive results in an immunoassay such as the EZ-Cup may reflect drugs or metabolites that are not detected by the confirmation testing available. It is likely that this latter scenario explains the false-positive benzodiazepine result observed in this study. These experiments clearly support the diagnostic capabilities of the drug testing device. However, it is important to note that the study is limited by the use of samples with a high prevalence population (24 positive/29 negative patient samples). The study was designed in this manner mainly for overall efficiency, but also because we expected the device to be utilized in facilities with high prevalence of drug abuse (such as rehabilitation and pain management centers) and not for the general population. A more broadly applicable study design would have been to test individuals at random and thus measure the predictive values of the device in a lower prevalence population. Government agencies require random and regular drug abuse testing. The initial screening cutoffs for the mandatory drug classes are published by the Substance Abuse and Mental Health Services Administration (SAMSHA) and were recently modified in May 2010 to be 50 ng/ml marijuana; 150 ng/ml cocaine; 2000 ng/ml opiates; 25 ng/ml phencyclidine; 500 ng/ml amphetamines; 500 ng/ml MDMA; and 10 ng/ml 6- acetylmorphine. With these cutoffs, this device would be appropriate for only MDMA, cocaine, and marijuana. Although this cup is not ideal for a SAMSHA-certified agency, the excellent performance of the screening cup encourages the validation and use of similar devices in institutions where rapid initial testing may be practical and advantageous. Acknowledgments The authors would like to thank Chantry Clark and Heidi Carlisle for their helpful laboratory assistance. We are grateful for the funding to support this study provided by ARUP Laboratories and the ARUP Institute for Clinical and Experimental Pathology. References 1. E. Lenters-Westra and R.J. Slingerland. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin. Chem. 56(1): (2010). 2. T.R. Gray, L.L. LaGasse, L.M. Smith, C. Derauf, P. Grant, R. Shah, A.M. Arria, S.A. Della Grotta, A. Strauss, W.F. Haning, B.M. Lester, and M.A. Huestis. Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther. Drug Monit. 31(6): (2009). 3. E.R. Harrison, J. Haaga, and T. Richards. Self-reported drug use data: what do they reveal? Am. J. Drug Alcohol Abuse 19(4): (1993). Manuscript received June 15, 2010; revision received July 21,

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Frederick G. Strathmann, PhD, DABCC, (CC,TC) Medical Director, Toxicology Associate Scientific Director of MS ARUP Laboratories

More information

Laboratory Service Report

Laboratory Service Report 4 05/25/19 Client C702884-DLP ROCHESTER Amphetamines, Confirmation Positive Confirmed POSITIVE by LC-S/S for the following: Amphetamine = 52 ethamphetamine = 124 ethamphetamine exists in the d- and l-isomeric

More information

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date

More information

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions September 2016 HCMC Toxicology Transition: Additional information and Frequently Asked Questions Many clinicians have asked for more information about the Urine Drug Compliance Analysis (LAB8742) switch

More information

DrugConfirm Advanced Instant Urine Drug Test Cups Training Guide.

DrugConfirm Advanced Instant Urine Drug Test Cups Training Guide. DrugConfirm Advanced Instant Urine Drug Test Cups Training Guide The information in this presentation is a general overview on using Confirm BioSciences DrugConfirm Advanced urine drug test cup; however,

More information

T R A I N I N G G U I D E

T R A I N I N G G U I D E TRAINING GUIDE InstaCube Oral Fluid Drug Test For Forensic Use Only Powered By: Contents 3 The information in this presentation is a general overview on performing and interpreting the InstaCube Oral Fluid

More information

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Adam S. Ptolemy 1, Colleen Murray 2, Edward Dunn 3,

More information

The Drug Testing Process. Employer or Practice

The Drug Testing Process. Employer or Practice Disclosures Clinical Professor, Jefferson Medical College BOD MROCC [Medical Review Officer Certification Council] BOD National Sleep Foundation BOD POEMS [Pennsylvania Occupational & Environmental Medicine

More information

A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography

A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography Application Note LCMS-109 A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography Time of Flight (LC-TOF) Mass Spectrometry Introduction Many clinical

More information

Rapid Alcohol Screening Devices. p19

Rapid Alcohol Screening Devices. p19 CLIA-WAIVED Product Catalog RAPID DRUG SCREENING DEVICES Rapid Urine Drug Screening Devices. p5 Rapid Alcohol Screening Devices. p19 Complementary Products. p23 HELPING YOU MAKE INFORMED DECISIONS ABOUT

More information

QuickTox Drug Screen Dipcard (with and without Adulteration Tests)

QuickTox Drug Screen Dipcard (with and without Adulteration Tests) QuickTox Drug Screen Dipcard (with and without Adulteration Tests) Training and Certification Program Presented by CLIAwaived.com, San Diego, CA Distributed by CLIAwaived.com www.cliawaived.com 1-858-481-5031

More information

QuickTox Drug Screen Dipcard (with and without Adulteration Tests)

QuickTox Drug Screen Dipcard (with and without Adulteration Tests) QuickTox Drug Screen Dipcard (with and without Adulteration Tests) Training and Certification Program Presented by Branan Medical Corporation Branan Medical Corporation 10015 Muirlands Road Irvine, California

More information

Fastect II Drug Screen Dipstick Test Training and Certification Program

Fastect II Drug Screen Dipstick Test Training and Certification Program Fastect II Drug Screen Dipstick Test Training and Certification Program Fastect II Training Page 1 of 7 Rev. B Fastect II Drug Screen Dipstick Test Training and Certification for Test Administrators The

More information

2013 Clinical drug and alcohol testing solutions. Product Catalog. CLIA-waived point of care test devices

2013 Clinical drug and alcohol testing solutions. Product Catalog. CLIA-waived point of care test devices 2013 Clinical drug and alcohol testing solutions Product Catalog CLIA-waived point of care test devices HELPING YOU MAKE INFORMED DECISIONS ABOUT ABUSE. Substance abuse testing with more substance. 2 of

More information

DrugConfirm Advanced Urine Dip Cards.

DrugConfirm Advanced Urine Dip Cards. DrugConfirm Advanced Urine Dip Cards The information in this presentation is a general overview on using the Confirm BioSciences DrugConfirm Advanced drug test cup but can be applied to many similarly

More information

Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens

Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens This document describes the validation of a Neogen Fentanyl kit for the semi-quantitative analysis of

More information

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG

More information

Learning Objectives. Drug Testing 10/17/2012. Utilization of the urine drug screen: The good, the bad, and the ugly

Learning Objectives. Drug Testing 10/17/2012. Utilization of the urine drug screen: The good, the bad, and the ugly Utilization of the urine drug screen: The good, the bad, and the ugly Jennifer A. Lowry, MD Chief, Section of Medical Toxicology Children s Mercy Hospital Kansas City, MO Learning Objectives Describe the

More information

EDUCATIONAL COMMENTARY METHADONE

EDUCATIONAL COMMENTARY METHADONE EDUCATIONAL COMMENTARY METHADONE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing Education

More information

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D. Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals

More information

Detection of Neonatal Drug Exposure Using Umbilical Cord Tissue and Liquid Chromatography Time-of-Flight Mass Spectrometry

Detection of Neonatal Drug Exposure Using Umbilical Cord Tissue and Liquid Chromatography Time-of-Flight Mass Spectrometry ORIGINAL ARTICLE Detection of Neonatal Drug Exposure Using Umbilical Cord Tissue and Liquid Chromatography Time-of-Flight Mass Spectrometry Stephanie J. Marin, PhD,* Anna Metcalf, BS, Matthew D. Krasowski,

More information

Urine drug testing it s not always crystal clear

Urine drug testing it s not always crystal clear Urine drug testing it s not always crystal clear Kirk Moberg, MD, PhD, FASAM Executive Medical Director, UnityPoint Health Illinois Institute for Addiction Recovery Clinical Professor of Internal Medicine

More information

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine Reporting Title: Pain Clinic Drug Screen, CoC, U Performing Location: Rochester Specimen Requirements: Container/Tube: Chain-of-Custody Kit (Supply T282) containing the specimen containers, seals, and

More information

Urine Drug Testing Methods 3-5

Urine Drug Testing Methods 3-5 Urine Drug Testing Methods 3-5 Type of Test Logistics Pearls Initial Screening Test: Immunoassay Confirmatory Test: Gas chromatography-mass spectrometry (GCMS) + or Liquid chromatography-mass spectrometry

More information

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching Liquid Chromatography Mass Spectrometry SSI-LCMS-8 LCMS-8 Drugs of Abuse: Analytes with Polarity Switching LCMS-8 Summary Seventy six analytes and their internal standards are described below. Multiple

More information

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016 Urine Drug Testing Methadone/Buprenorphine 101 Workshop Ron Joe, MD, DABAM December 10, 2016 Learning objectives Clarify the purpose of urine drug testing (UDT) Distinguish between UDT for detection of

More information

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital What Your Drug Test Really Means Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital Disclosure There are no relevant financial relationships with commercial interests associated.

More information

INTERPATH LABORATORY, INC. TEST UPDATES

INTERPATH LABORATORY, INC. TEST UPDATES EFFECTIVE DATE: February 16, 2016 INTERPATH LABORATORY, INC. TEST UPDATES Please take note of the following test updates and make the appropriate changes in your Interpath Service Manual. Feel free to

More information

DRUGS OF ABUSE

DRUGS OF ABUSE DRUGS OF ABUSE www.btnx.com 1-888-339-9964 Rapid Response Drugs of Abuse and Alcohol Screening Devices BTNX Inc. prides itself in offering quality drug detection tests for accurate, safe and rapid testing.

More information

Validation of an Automated Method to Remove

Validation of an Automated Method to Remove Shahana Wahab Huq 1, Richard Thomas 2, Agnes Cua 2, Seyed Sadjadi 1 1 Phenomenex, 411 Madrid Avenue, Torrance, CA 951 2 Precision Toxicology, 33 Bunker Hill Street, San Diego, CA 9219 Validation of an

More information

A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS

A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS Introduction Drug analysis from whole blood is gaining popularity due to a more complete measurement

More information

Urine Opioid Dependency Panel (UODP) 1

Urine Opioid Dependency Panel (UODP) 1 Drug Testing Panels Urine Opioid Dependency Panel (UODP) 1 Amphetamines Amphetamine Methamphetamine Methylenedioxyamphetamine Adderall, Dexedrine, Vyvanse, Lisdexamfetamine (Speed, Bennies, Crystal Meth,

More information

PROFESSIONALISM AND COMMENTARY. Optimizing Urine Drug Testing for Monitoring Medication Compliance in Pain Management

PROFESSIONALISM AND COMMENTARY. Optimizing Urine Drug Testing for Monitoring Medication Compliance in Pain Management bs_bs_banner Pain Medicine 2013; 14: 1813 1820 Wiley Periodicals, Inc. PROFESSIONALISM AND COMMENTARY Optimizing Urine Drug Testing for Monitoring Medication Compliance in Pain Management Disclosure: The

More information

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up Dr. Bhushan M. Kapur Associate Professor Department of Laboratory Medicine and Pathobiology, Faculty

More information

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA Disclaimer

More information

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain Faculty Disclosure Henry C. Nipper, PhD, DABCC Dr. Nipper has listed no financial interest/arrangement that would be considered a conflict of interest. Urine Drug Testing to Monitor Opioid Use In Managing

More information

Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature. Distributed to # of Copies Distributed to # of Copies

Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature. Distributed to # of Copies Distributed to # of Copies Procedure: Status DS Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature Distributed to # of Copies Distributed to # of Copies PRINCIPLE: The Status DS 10 Panel (MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP)

More information

Drug & Alcohol Testing in. Canada. Point of Care Testing

Drug & Alcohol Testing in. Canada. Point of Care Testing Drug & Alcohol Testing in Canada Point of Care Testing Introduction We are the leading Canadian innovator of diagnostic testing products and services Verify Diagnostics has assisted governments, corporations,

More information

POINT OF CARE TESTING

POINT OF CARE TESTING POINT OF CARE TESTING POINT OF CARE INSTANT TESTING Randox Testing Services offers a wide range of products to enable you to carry out on-site drug and alcohol testing for instant results. Our products

More information

Opiates Rapid Test. Cat. No.:DTS137 Pkg.Size:50T. Intended use. General Description. Principle Of The Test. Reagents And Materials Provided

Opiates Rapid Test. Cat. No.:DTS137 Pkg.Size:50T. Intended use. General Description. Principle Of The Test. Reagents And Materials Provided Opiates Rapid Test Cat. No.:DTS137 Pkg.Size:50T Intended use The CD One Step Opiates Screening Test is a rapid, qualitative immunoassay for the detection of opiates and opiate metabolites in urine. The

More information

ToxCup Drug Screen Cup (with and without Adulteration Tests) Training and Certification Program

ToxCup Drug Screen Cup (with and without Adulteration Tests) Training and Certification Program ToxCup Drug Screen Cup (with and without Adulteration Tests) Training and Certification Program ToxCup Training Page 1 of 8 Rev. B ToxCup Drug Screen Cup ToxCup Drug Screen Cup with Adulteration Tests

More information

URINE DRUG TOXICOLOGY

URINE DRUG TOXICOLOGY Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences URINE DRUG TOXICOLOGY Suzanne E. Rapp, MD GENERAL DISCLOSURES The University of Washington School of Medicine also

More information

Physician s Reference for Urine and Blood Drug Testing and Interpretation

Physician s Reference for Urine and Blood Drug Testing and Interpretation Physician s Reference for Urine and Blood Drug Testing and Interpretation DETECTIMED PANEL Urine (test code 70195) Screen Confirmation Screen Confirmation Alcohol Ethanol Amphetamines Amphetamine Methamphetamine

More information

European Guidelines for Workplace Drug Testing in UrineandOral fluid

European Guidelines for Workplace Drug Testing in UrineandOral fluid EWDTS European Workplace Drug Testing Society European Guidelines for Workplace Drug Testing in UrineandOral fluid 9th EWDTS Symposium in Lisbon Sanna Taskinen Michaela Neuhofer Updating project # 2 Current

More information

nextgen precision Test Report

nextgen precision Test Report nextgen precision TM Test Report SUMMARY OF PRECISION S NEXTGEN TEST REPORT In an effort to provide as much clinical insight as possible to our providers, we created our comprehensive NextGen Precision

More information

Drug Adherence Assessment Report

Drug Adherence Assessment Report Prescribed Medications: Drug Adherence Assessment Report FENTANYL, OXYCODONE CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST PRESCRIPTION (S)

More information

Toxicology Testing Is it a Good Fit for Your Laboratory? Rebecca Kenner, BA, MT, DLM(ASCP) Leigh Ann Smith, BS, MLS(ASCP), CLS

Toxicology Testing Is it a Good Fit for Your Laboratory? Rebecca Kenner, BA, MT, DLM(ASCP) Leigh Ann Smith, BS, MLS(ASCP), CLS Thursday April 6, 2017 B16 Toxicology Testing Is it a Good Fit for Your Laboratory? Rebecca Kenner, BA, MT, DLM(ASCP) Leigh Ann Smith, BS, MLS(ASCP), CLS Global Analytical Development DESCRIPTION: Are

More information

Test Definition: PCDSO Pain Clinic Drug Screen, Urine

Test Definition: PCDSO Pain Clinic Drug Screen, Urine Reporting Title: Pain Clinic Drug Screen, U Performing Location: Rochester Specimen Requirements: Collection Container/Tube: Plastic urine container Submission Container/Tube: Plastic, 60-mL urine bottle

More information

ToxCup Drug Screen Cup (with and without Adulteration Tests) Training and Certification Program

ToxCup Drug Screen Cup (with and without Adulteration Tests) Training and Certification Program ToxCup Drug Screen Cup (with and without Adulteration Tests) Training and Certification Program ToxCup Training Page 1 of 8 Rev. B ToxCup Drug Screen Cup ToxCup Drug Screen Cup with Adulteration Tests

More information

You Can t Fool the Bladder Police. Effective Use of Urine Drug Screening

You Can t Fool the Bladder Police. Effective Use of Urine Drug Screening You Can t Fool the Bladder Police Effective Use of Urine Drug Screening Why Test? Accountability Create and maintain safe treatment environment Compliance with licensing or policy Collection Supervised

More information

Overview of the AACC Academy s LMPG: Using clinical laboratory tests to monitor drug therapy in pain management patients

Overview of the AACC Academy s LMPG: Using clinical laboratory tests to monitor drug therapy in pain management patients Overview of the AACC Academy s LMPG: Using clinical laboratory tests to monitor drug therapy in pain management patients Gwen McMillin, PhD, DABCC(CC,TC) Professor, University of Utah Medical Director,

More information

SalivaConfirm Premium

SalivaConfirm Premium SalivaConfirm Premium Substance Abuse Oral Screening Device salivaconfirm oral fluid multi-drug screening kit The information in this presentation is a general overview on using the Confirm BioSciences

More information

CARE ABOUT YOUR HEALTH

CARE ABOUT YOUR HEALTH WE CARE ABOUT YOUR HEALTH THE REVOLUTION OF MEDICINE DO IT YOURSELF US FDA 510(k)OTC Cleared/Exempt CLIA Waived FERTILITY TESTS SPEED ACCURACY EXCELLENCE HCG PREGNANCY TEST HLH OVULATION TEST* HFSH MENOPAUSE

More information

Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS

Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS Application Note Forensics Authors Jason Hudson, Ph.D., James Hutchings, Ph.D., and Rebecca Wagner, Ph.D. Virginia Department

More information

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082 Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending

More information

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date: Payment Policy: Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey

Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey Kayla J. Lowrie, MS, Jennifer Turri, BS, Jill Yeakel, MSFS, Barry K. Logan, PhD, DABFT, Arcadia University, 450 S. Easton

More information

EDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing

EDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing EDUCATIONAL COMMENTARY 2003 3 rd TEST EVENT Chemistry Urine Drug Testing Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE

More information

INSTANT DRUG SCREENING

INSTANT DRUG SCREENING ................................ INSTANT DRUG SCREENING Rapid tests for the detection of drugs and their metabolites in urine and saliva A CEuropean Background NHS Supply Chain Approved Reliable, quick

More information

DrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.

DrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc. Accuracy The accuracy of the DrugSmart Drugs of Abuse Tests was evaluated in comparison to commercially available drug screen tests. Sixty (60) negative urine samples collected from presumed non-user volunteers

More information

Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab

Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab Application Note Clinical Research Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab Authors Adam Barker 1,2, Frederick G. Strathmann 3, Natalie N. Rasmussen 4, and Carrie

More information

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J. Drug Adherence Assessment Report Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED PRESCRIPTION FLAG ANTICIPATED

More information

Forensic Toxicology Scope of Testing and Detection Limits

Forensic Toxicology Scope of Testing and Detection Limits Forensic Toxicology Scope of Testing and Detection Limits Table of Contents QUALITATIVE ANALYSES... 2 Volatile Screen by GC/FID... 2 Carbon Monoxide by Microdiffusion... 2 Ethylene Glycol by GC/MS... 2

More information

The Utility of Urine Drug Screening

The Utility of Urine Drug Screening The Utility of Urine Drug Screening Treating Addiction, Saving Lives Sea Cruises Bye Tazmania, still far from New Zealand February 8 th, 2018 Mandy Manak, MD FASAM, ISAM, CSAM, MRO Medical Director, ICDO

More information

Pain Medication Management Program Supports Patient Outcomes and Adherence

Pain Medication Management Program Supports Patient Outcomes and Adherence PeaceHealth Laboratories UPDATE 2015 Revised Edition Pain Medication Management Program Supports Patient Outcomes and Adherence BENEFITS Monitors analgesic medication adherence to ensure patient safety

More information

Welcome - SAMHSA s Role. Welcome SAMHSA Key Messages 4. Welcome SAMHSA s Direction

Welcome - SAMHSA s Role. Welcome SAMHSA Key Messages 4. Welcome SAMHSA s Direction Welcome - SAMHSA s Role 2 Welcome and Opening Remarks The National Conference on Substance Abuse, Child Welfare and the Courts Division of Workplace Programs Ron R. Flegel, BSMT, M.S. and Charles Lodico,

More information

Product Catalog. Rapid Alcohol Screening Devices. p24. Rapid Urine Screening Devices. p4. Rapid Oral Fluid Screening Devices. p18

Product Catalog. Rapid Alcohol Screening Devices. p24. Rapid Urine Screening Devices. p4. Rapid Oral Fluid Screening Devices. p18 2014 Product Catalog Rapid Urine Screening Devices. p4 Rapid Oral Fluid Screening Devices. p18 Rapid Alcohol Screening Devices. p24 Complementary Products. p32 Product Catalog HELPING YOU MAKE INFORMED

More information

Drug Screening: Things You Need to Know

Drug Screening: Things You Need to Know Drug Screening: Things You Need to Know (a view inside the clinical laboratory) Gary L. Horowitz, MD Director, Clinical Chemistry, Beth Israel Deaconess Medical Center Associate Professor of Pathology,

More information

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK ccredited to Laboratory locations: Gavenny Court Brecon Road bergavenny Monmouthshire

More information

MEDICAL POLICY Drug Testing

MEDICAL POLICY Drug Testing POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 11/13/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each

More information

Pain Medication Management Program Monitors Patient Compliance

Pain Medication Management Program Monitors Patient Compliance PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your

More information

Schedule of Accreditation

Schedule of Accreditation Schedule of Accreditation Organisation Name Trading As INAB Reg No Contact Name Address Medical Bureau Of Road Safety 30T Helen Kearns Contact Phone No 01-7165555 Email Website Accreditation Standard Health

More information

Your Results are Our Priority.

Your Results are Our Priority. Your Results are Our Priority. Enzyme Linked Immunosorbent Assay (ELISA) One year shelf life Ready to use, color coded reagents and bottles Single dilution factor Adaptable for all forensic matrices Forensic

More information

DRUG TEST CATALOG. Alpha Drug Testing Services, LLC. Dip & Reads. Clia Waived Cups. Breathalyzers. Pipette Tests. Alcohol Tests.

DRUG TEST CATALOG. Alpha Drug Testing Services, LLC. Dip & Reads. Clia Waived Cups. Breathalyzers. Pipette Tests. Alcohol Tests. DRUG TEST CATALOG Dip & Reads Clia Waived Cups Breathalyzers Pipette Tests Alcohol Tests Nicotine Tests Drug Test Cups Saliva Drug Tests Collection Supplies Alpha Drug Testing Services, LLC 965 Murphy

More information

LC Application Note. Dangerous driver?

LC Application Note. Dangerous driver? LC Application Note Dangerous driver? www.palsystem.com Dangerous driver? Robert M. Sears 1 ; Kenneth C. Lewis 2 ; and Kim Gamble 3 1 SC Law Enforcement Division, Columbia, SC 29221; 2 OpAns LLC, Durham

More information

Contract No. 952-M1 Collection Service Requirements Texas Department of Criminal Justice (TDCJ)

Contract No. 952-M1 Collection Service Requirements Texas Department of Criminal Justice (TDCJ) The services and requirements referenced are specific to Texas Department of Criminal Justice (TDCJ) and are in addition to and may include the services and must be in compliance with the requirements

More information

Rapid Hydrolysis of Benzodiazepines in Urine. Alicia Zook 1 and Crystal Xander B.S. 2. Cedar Crest College, Allentown, PA 1

Rapid Hydrolysis of Benzodiazepines in Urine. Alicia Zook 1 and Crystal Xander B.S. 2. Cedar Crest College, Allentown, PA 1 Rapid Hydrolysis of Benzodiazepines in Urine Alicia Zook 1 and Crystal Xander B.S. 2 Cedar Crest College, Allentown, PA 1 Health Network Laboratories, Allentown, PA 2 Abstract: Benzodiazepines are sedative/hypnotic

More information

Testing for Controlled Substances

Testing for Controlled Substances Testing for illicit drugs Testing for Controlled Substances 1 Purposes: Employment Sports Screening medical eval. Legal Monitoring Treatment Probation Prescribing controlled substances Forensics 2 Drug

More information

Cutoff levels for hydrocodone in a blood test

Cutoff levels for hydrocodone in a blood test Cutoff levels for hydrocodone in a blood test The premier DNA and drug testing company in the North Texas area. Specializing in legal cases but also provide testing for employers and private individuals.

More information

High-Throughput Quantitative LC-MS/MS Analysis of 6 Opiates and 14 Benzodiazepines in Urine

High-Throughput Quantitative LC-MS/MS Analysis of 6 Opiates and 14 Benzodiazepines in Urine High-Throughput Quantitative LC-MS/MS Analysis of and 14 Benzodiazepines in Urine Bill Yu, Kristine Van Natta, Marta Kozak, Thermo Fisher Scientific, San Jose, CA Application Note 588 Key Words Opiates,

More information

Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis of Basic Drugs

Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis of Basic Drugs Seyed Sadjadi, Shahana Huq, Sean Orlowicz and Laura Snow Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis

More information

Welcome! Supreme Court of Ohio Specialized Dockets Conference. October 23-24, 2017

Welcome! Supreme Court of Ohio Specialized Dockets Conference. October 23-24, 2017 Welcome! Supreme Court of Ohio Specialized Dockets Conference October 23-24, 2017 Drug Testing: Do you know enough to be dangerous? Presented by William L. Parker President & CEO American Court & Drug

More information

ONLINE DAT II Results matter.

ONLINE DAT II Results matter. From tough questions to reliable answers. ONLINE DAT II Results matter. Patient results matter Reputations are at stake: theirs and yours. Behind every Drugs-of-Abuse Test (DAT) result is a person whose

More information

80305, 80306, 80307,G0480, G0481, G0482, G0483, G0659

80305, 80306, 80307,G0480, G0481, G0482, G0483, G0659 80305, 80306, 80307,G0480, G0481, G0482, G0483, G0659 CMS Policy for Connecticut, Maine, Massachusetts, New Hampshire, New York, Rhode Island, and Vermont Local policies are determined by the performing

More information

Powering Efficient Behavioral Health Care Services

Powering Efficient Behavioral Health Care Services Powering Efficient Behavioral Health Care Services Streamlining behavioral health care decisions through comprehensive and efficient drug monitoring Quest Diagnostics has you and your patients covered

More information

Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Prepared and presented by Jennifer Bolen, JD Disclosures for Jennifer Bolen, JD Consultant - Generation

More information

DAU. Scheme Description. Drugs of Abuse in Urine Proficiency Testing Scheme

DAU. Scheme Description. Drugs of Abuse in Urine Proficiency Testing Scheme DAU Drugs of Abuse in Urine Proficiency Testing Scheme Scheme Description LGC Standards Proficiency Testing 1 Chamberhall Business Park Chamberhall Green Bury Lancashire BL9 0AP United Kingdom Telephone:

More information

Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.

Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K. Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K. Logan FSF Emerging Forensic Scientist Award Oral Presentation Disclosure

More information

Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1

Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1 Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications dr. Jan Srbek, HPST Page 1 Major LC-MS Clinical Applications Steroids/Endocrinology Vitamin D Testosterone, Estradiol

More information

1060 Holland Dr: Suite A Boca Raton, FL Nationwide: (877) Local: (561) Fax: (561)

1060 Holland Dr: Suite A Boca Raton, FL Nationwide: (877) Local: (561) Fax: (561) 1060 Holland Dr: Suite A Boca Raton, FL 33487 Nationwide: (877) 722-6339 Local: (561) 288-9028 Fax: (561) 288-3929 http://www.claritydiagnostics.com Safety Data Sheet Section 1: Identification Product

More information

Drugs of Abuse I Serum

Drugs of Abuse I Serum Drugs of Abuse I Serum 2017-11 1.10 For quality monitoring of quantitative measurements by chromatographic methods These reference materials are produced on the basis of human matrices. The highly accurate

More information

Mass Spectrometry in Precision Medicine --A Penn Experience in Metabolomics and TDM

Mass Spectrometry in Precision Medicine --A Penn Experience in Metabolomics and TDM Mass Spectrometry in Precision Medicine --A Penn Experience in Metabolomics and TDM Ping Wang, PhD, DABCC, FACB Chief of Clinical Chemistry Director of Core Laboratory Hospital of University of Pennsylvania

More information

Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids

Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids PO-CON1753E Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids ASMS 2017 TP-442 Joshua F. Emory 1, Nathan DeFreitas 2, Michael Roberts 1, Manoj Tyagi 2, M.

More information

10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Prepared and presented by Jennifer Bolen, JD Disclosures for Jennifer Bolen, JD Consultant - Generation

More information

BETA-GLUCURONIDASE PRODUCT LINE INNOVATION THROUGH CHEMISTRY. FORENSICS

BETA-GLUCURONIDASE PRODUCT LINE INNOVATION THROUGH CHEMISTRY.   FORENSICS FORENSICS BETA-GLUCURONIDASE PROD LINE INNOVATION THROUGH CHEMISTRY ABALONASE Purified Beta-Glucuronidase Formula Clean, Rapid And Reliable Shown from left to right: Abalonase purified Beta-glucuronidase

More information

Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspective

Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspective Article in press - uncorrected proof Clin Chem Lab Med 2009;47(8):971 976 2009 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2009.220 2009/180 Analysis and interpretation of drug testing results

More information

Controlled Substance Monitoring in the Age of the Opioid Epidemic

Controlled Substance Monitoring in the Age of the Opioid Epidemic Controlled Substance Monitoring in the Age of the Opioid Epidemic Paul E. Hilliard, MS, MD Hospital Pain Committee Chair Department of Anesthesiology CME housekeeping I have no financial disclosures AKA,

More information

Urine Drug Screening: The Essentials of Interpretation

Urine Drug Screening: The Essentials of Interpretation Urine Drug Screening: The Essentials of Interpretation Loralie J Langman, PhD DABCC (CC, MD, TC), F-ABFT Director Clinical and Forensic Toxicology Laboratory, Mayo Clinic Professor, Mayo Clinic College

More information

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) 1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory

More information

Drug Testing: How to Evaluate Results

Drug Testing: How to Evaluate Results Drug Testing: How to Evaluate Results Prepared for you by the West Virginia Drug Testing Laboratory Drug testing, whether for an individual or a large corporation, consists of two necessary steps - specimen

More information